TIDMHIK 
 
RNS Number : 4622G 
Hikma Pharmaceuticals Plc 
01 February 2010 
 

 
 
 
              Hikma Pharmaceuticals PLC - Voting Rights and Capital 
 
LONDON, 1 February 2010 Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) 
notifies the market that as at 1 February 2010 its capital consists of 
191,627,607 ordinary shares with voting rights. There are no shares held in 
treasury. 
 
The above figure (191,627,607) may be used by shareholders as the denominator 
for the calculations by which they will determine if they are required to notify 
their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC 
under the FSA's Disclosure and Transparency Rules. 
 
                                    - ENDS - 
 
Enquiries: 
 
+-----------------------------------------+----------------------------------------------+ 
| Hikma Pharmaceuticals PLC               |                                              | 
+-----------------------------------------+----------------------------------------------+ 
| Henry Knowles                           | +44 20 7399 2760                             | 
| Company Secretary                       |                                              | 
|                                         |                                              | 
+-----------------------------------------+----------------------------------------------+ 
|                                         |                                              | 
+-----------------------------------------+----------------------------------------------+ 
 
 
 
About Hikma 
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on 
developing, manufacturing and marketing a broad range of both branded and 
non-branded generic and in-licensed pharmaceutical products.  Hikma's operations 
are conducted through three businesses: "Branded", "Injectables" and "Generics". 
 Hikma's operations are based principally in the Middle East and North Africa 
("MENA") region, where it is a market leader and sells across 17 countries, the 
United States and Europe.  In 2008, the Group achieved revenues of $580.7 
million (2007 $449 million) and profit attributable to shareholders was $57.1 
million (2007 $63 million).  For news and other information, please visit 
www.hikma.com. 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 TVREADAFEDNEEFF
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.